Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.61 |
| ▸ | TFPI | P10646 | 6/20 | 0.60 |
| ▸ | MC4R | P32245 | 1/20 | 0.57 |
| ▸ | MC5R | P33032 | 1/20 | 0.57 |
| ▸ | MC3R | P41968 | 1/20 | 0.57 |
| ▸ | MC1R | Q01726 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | KDM5A | P29375 | 1/20 | 0.56 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 2/20 | 0.55 |
| ▸ | NPY4R | P50391 | 2/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.55 |
| ▸ | NPY1R | P25929 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14479418 | 0.97 | KDM1A (0.61) | KDM1ATFPIOPRM1OPRK1MAOB | |
| SCHEMBL14479371 | 0.95 | KDM1A (0.60) | KDM1ATFPIMC4RMC5RMC3R | |
| SCHEMBL14479444 | 0.94 | KDM1A (0.62) | KDM1ATFPIMAOBKDM5AKDM1B | |
| SCHEMBL16976105 | 0.93 | KDM1A (0.61) | KDM1ATFPIMAOBKDM5AKDM1B | |
| SCHEMBL14479342 | 0.93 | KDM1A (0.61) | KDM1ATFPIMAOBKDM5AKDM1B | |
| SCHEMBL14479329 | 0.93 | KDM1A (0.61) | KDM1ATFPIMAOBKDM5AKDM1B | |
| SCHEMBL14479411 | 0.93 | KDM1A (0.60) | KDM1ATFPIMAOBKDM5AKDM1B | |
| SCHEMBL14479427 | 0.93 | KDM1A (0.60) | KDM1ATFPIMAOBKDM5AKDM1B | |
| SCHEMBL16976076 | 0.92 | KDM1A (0.62) | KDM1ATFPIOPRM1OPRK1MAOB | |
| SCHEMBL14479434 | 0.91 | KDM1A (0.61) | KDM1ATFPIOPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9155795-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130005944-A1 | CXCR4 Receptor Compounds | ACER THERAPEUTICS INC. | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005944-A1 | CXCR4 Receptor Compounds | CXCL12, CXCR4, CCR5 | KDM1A 4032/4885TFPI 1747/4885MC4R 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.